NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.
Structured Abstract
Background:
Prior reviews on hepatitis C (HCV) infection screening and treatment used by the U.S. Preventive Services Task Force (USPSTF) to inform its 2013 recommendation found interferon-containing antiviral therapies associated with sustained virologic response (SVR) rates of 68 percent to 78 percent and an association between SVR after antiviral therapy and improved clinical outcomes. Interferon-containing regimens were associated with a high rate of harms. Since the prior reviews, interferon-containing antiviral therapies have been replaced by all-oral direct acting antiviral (DAA) regimens.
Purpose:
To systematically review the evidence on screening for HCV infection in asymptomatic adults and adolescents, including effects of DAA regimens and interventions to prevent mother-to-child transmission.
Data Sources:
We searched the Cochrane Central Register of Controlled Trials and Cochrane Database of Systematic Reviews, Ovid MEDLINE and ClinicalTrials.gov through February 2019, manually reviewed reference lists, and conducted literature surveillance through November 22, 2019.
Study Selection:
Randomized controlled trials (RCTs), non-randomized trials, and cohort studies of HCV screening, antiviral therapy, and interventions to prevent mother-to-child transmission of HCV infection on SVR and clinical outcomes; and cohort studies on the association between an SVR after antiviral therapy versus no SVR and clinical outcomes. Treatment studies focused on populations without cirrhosis who are more likely to be asymptomatic and identified by screening.
Data Extraction:
One investigator abstracted data, and a second investigator checked data abstraction for accuracy. Two investigators independently assessed study quality using methods developed by the USPSTF.
Data Synthesis (Results):
No study evaluated the benefits of HCV screening versus no screening, or the yield of repeat versus one-time screening. Previously reviewed studies found that HCV screening might be associated with negative psychological and social consequences, but had important methodological limitations; no new studies were identified. One new study found similar diagnostic yield of risk-based and birth cohort screening, but it was retrospective and assumed perfect implementation of risk-based screening. Ten trials reported improvements in some quality of life and functional outcomes following DAA treatment compared with prior to treatment, but differences were small, studies were open-label, and there was no non-DAA comparison group. Forty-nine trials found DAA regimens associated with pooled SVR rates that ranged from 95.5 percent to 98.9 percent across genotypes; rates of serious adverse events (1.9%) and withdrawal due to adverse events (0.4%) were low. Seven trials reported SVR rates in adolescents with DAA therapy similar to those observed in adults. An SVR after antiviral therapy was associated with decreased risk of all-cause mortality (13 studies, pooled hazard ratio [HR] 0.40, 95% confidence interval [CI] 0.28 to 0.56), liver mortality (4 studies, pooled HR 0.11, 95% CI, 0.04 to 0.27), cirrhosis (4 cohorts in 3 studies, pooled HR 0.36, 95% CI, 0.33 to 0.40), and hepatocellular carcinoma (20 studies, pooled HR 0.29, 95% CI, 0.23 to 0.38) versus no SVR, after adjustment for potential confounders. New evidence on interventions to reduce the risk of mother-to-infant transmission was limited and did not change the conclusion from the prior review that no intervention has been clearly demonstrated to reduce risk.
Limitations:
Most DAA trials were not randomized and did not have a non-DAA comparison group, almost all DAA trials relied on SVR as the main efficacy outcome, observational studies varied in how well they adjusted for confounders, and few studies evaluated the effectiveness of DAA regimens in adolescents.
Conclusions:
The USPSTF previously determined that HCV screening is highly accurate. Currently recommended all-oral DAA regimens are associated with very high SVR rates (95.5% to 98.9% across genotypes) and few harms relative to older antiviral therapies. An SVR after antiviral therapy is associated with improved clinical outcomes compared with no SVR, after adjusting for potential confounders. Direct evidence on the benefits of HCV screening remains unavailable, and direct evidence on the effects of antiviral therapy on clinical outcomes remains limited but indicates improved long-term outcomes.
Contents
- Acknowledgments
- Chapter 1. Introduction and Background
- Chapter 2. Methods
- Chapter 3. Results
- Key Question 1a. Does Screening for HCV Infection in Pregnant and Nonpregnant Adolescents and Adults Without Known Abnormal Liver Enzyme Levels Reduce HCV-Related Mortality and Morbidity or Affect Quality of Life?
- Key Question 1b. Does Prenatal Screening for HCV Infection Reduce Risk of Vertical Transmission of HCV Infection?
- Key Question 2. What Is the Effectiveness of Different Risk- or Prevalence-Based Methods for Screening for HCV Infection on Clinical Outcomes?
- Key Question 3. What Is the Yield (Number of New Diagnoses per Tests Performed) of One-Time vs. Repeat Screening or Alternative Screening Strategies for HCV Infection, and How Does the Screening Yield Vary in Different Risk Groups?
- Key Question 4. What Are the Harms of Screening for HCV Infection (e.g., Anxiety and Labeling)?
- Key Question 5. What Are the Effects of Interventions During Labor and Delivery or the Perinatal Period on Risk of Vertical Transmission of HCV Infection?
- Key Question 6. What Is the Effectiveness of Currently Recommended Antiviral Treatments in Improving Health Outcomes in Patients With HCV Infection?
- Key Question 7. What Is the Effectiveness of Currently Recommended Antiviral Treatments in Achieving a SVR in Patients With HCV Infection?
- Key Question 8. What Are the Harms of Currently Recommended Antiviral Treatments?
- Key Question 9. What Is the Association Between Experiencing SVR Following Antiviral Treatment and Reduction in Risk of HCV-Related Adverse Health Outcomes?
- Contextual Question 1. Based on Population Level Estimates, What Are Recent Trends in the Epidemiology, Prevalence, and Incidence of HCV Infection in the United States, Including in Primary Care Settings, Over the Past 5 to 10 Years?
- Contextual Question 2. What Are the Effects of Different Risk- or Prevalence-Based Methods for Screening for HCV Infection in Modeling Studies?
- Contextual Question 3. What Is the Effect of Antiviral Treatments on Behavioral Outcomes?
- Chapter 4. Discussion
- References
- Appendixes
Suggested citation:
Chou R, Dana T, Fu R, Zakher B, Wagner J, Ramirez S, Grusing S, Jou JH. Screening for Hepatitis C Virus Infection in Adolescents and Adults: A Systematic Review Update for the U.S. Preventive Services Task Force. Evidence Synthesis No. 188. AHRQ Publication No. 19-05256-EF-1. Rockville, MD: Agency for Healthcare Research and Quality; 2020.
This report is based on research conducted by the Pacific Northwest Evidence-based Practice Center (EPC) under contract to the Agency for Healthcare Research and Quality, Rockville, MD (Contract No. HHSA-290-2015-00009-I, Task Order No. 7). The findings and conclusions in this document are those of the authors, who are responsible for its contents, and do not necessarily represent the views of the Agency for Healthcare Research and Quality. Therefore, no statement in this report should be construed as an official position of Agency for Healthcare Research and Quality or of the U.S. Department of Health and Human Services.
The information in this report is intended to help health care decision makers—patients and clinicians, health system leaders, and policymakers, among others—make well-informed decisions and thereby improve the quality of health care services. This report is not intended to be a substitute for the application of clinical judgment. Anyone who makes decisions concerning the provision of clinical care should consider this report in the same way as any medical reference and in conjunction with all other pertinent information (i.e., in the context of available resources and circumstances presented by individual patients).
This report may be used, in whole or in part, as the basis for development of clinical practice guidelines and other quality enhancement tools, or as a basis for reimbursement and coverage policies. Agency for Healthcare Research and Quality or U.S. Department of Health and Human Services endorsement of such derivative products may not be stated or implied.
None of the investigators have any affiliations or financial involvement that conflicts with the material presented in this report.
- NLM CatalogRelated NLM Catalog Entries
- Screening for Hepatitis C Virus Infection in Adolescents and Adults: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force.[JAMA. 2020]Screening for Hepatitis C Virus Infection in Adolescents and Adults: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force.Chou R, Dana T, Fu R, Zakher B, Wagner J, Ramirez S, Grusing S, Jou JH. JAMA. 2020 Mar 2; . Epub 2020 Mar 2.
- Review Lipid Screening in Childhood and Adolescence for Detection of Familial Hypercholesterolemia: A Systematic Evidence Review for the U.S. Preventive Services Task Force[ 2016]Review Lipid Screening in Childhood and Adolescence for Detection of Familial Hypercholesterolemia: A Systematic Evidence Review for the U.S. Preventive Services Task ForceLozano P, Henrikson NB, Dunn J, Morrison CC, Nguyen M, Blasi PR, Anderson ML, Whitlock E. 2016 Aug
- Review Lipid Screening in Childhood for Detection of Multifactorial Dyslipidemia: A Systematic Evidence Review for the U.S. Preventive Services Task Force[ 2016]Review Lipid Screening in Childhood for Detection of Multifactorial Dyslipidemia: A Systematic Evidence Review for the U.S. Preventive Services Task ForceLozano P, Henrikson NB, Morrison CC, Dunn J, Nguyen M, Blasi P, Whitlock EP. 2016 Aug
- Review Screening for HIV Infection in Pregnant Women: A Systematic Review for the U.S. Preventive Services Task Force[ 2019]Review Screening for HIV Infection in Pregnant Women: A Systematic Review for the U.S. Preventive Services Task ForceSelph SS, Bougatsos C, Dana T, Grusing S, Chou R. 2019 Jun
- Review Screening for Hepatitis B Virus Infection in Nonpregnant Adolescents and Adults: A Systematic Review for the U.S. Preventive Services Task Force[ 2020]Review Screening for Hepatitis B Virus Infection in Nonpregnant Adolescents and Adults: A Systematic Review for the U.S. Preventive Services Task ForceChou R, Blazina I, Bougatsos C, Holmes R, Selph S, Grusing S, Jou J. 2020 Dec
- Screening for Hepatitis C Virus Infection in Adolescents and Adults: A Systemati...Screening for Hepatitis C Virus Infection in Adolescents and Adults: A Systematic Review Update for the U.S. Preventive Services Task Force
Your browsing activity is empty.
Activity recording is turned off.
See more...